Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37–50.

Article  CAS  PubMed  Google Scholar 

Krummel M. Nobel notes value of basic research for new drugs. Nature. 2018;563(7730):184.

Article  CAS  PubMed  Google Scholar 

Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize. Nature. 2018;562(7725):20–1.

Article  CAS  PubMed  Google Scholar 

Barone B, Calogero A, Scafuri L, Ferro M, Lucarelli G, Di Zazzo E, et al. Immune checkpoint inhibitors as a neoadjuvant/adjuvant treatment of muscle-invasive bladder cancer: a systematic review. Cancers. 2022;14(10):2545r.

Article  Google Scholar 

Iacovino ML, Miceli CC, De Felice M, Barone B, Pompella L, Chiancone F, et al. Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers: a new horizon opened by molecular classification and immune checkpoint inhibitors. Int J Mol Sci. 2022;23(3):1133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sugiura D, Maruhashi T, Okazaki IM, Shimizu K, Maeda TK, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019;364(6440):558–66.

Article  CAS  PubMed  Google Scholar 

Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maghrouni A, Givari M, Jalili-Nik M, Mollazadeh H, Bibak B, Sadeghi MM, et al. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: preclinical evidence and clinical interventions. Int Immunopharmacol. 2021;93:107403.

Article  CAS  PubMed  Google Scholar 

Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.

Article  PubMed  Google Scholar 

Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol. 2022:[JCO2200221 p.]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35867951.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

Article  PubMed  PubMed Central  Google Scholar 

Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942–50.

Article  CAS  PubMed  Google Scholar 

Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 checkmate 227 part 1 trial. J Thorac Oncol. 2022;17(2):289–308.

Article  CAS  PubMed  Google Scholar 

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239–53.

Article  CAS  PubMed  Google Scholar 

D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein O, Kee D, Gao B, Markman B, da Gama DJ, Quigley L, et al. Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209–538 clinical trial. J Immunother Cancer. 2021;9(11):e003156.

Article  PubMed  PubMed Central  Google Scholar 

Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 2020;6(10):1563–70.

Article  PubMed  Google Scholar 

Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey J-N, Lee SS, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208–18.

Article  PubMed  PubMed Central  Google Scholar 

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657–65.

Article  PubMed  Google Scholar 

Markmitch. Engauge Digitizer 4.1 https://engauge-digitizer.updatestar.com/: Updatestar; 2008 [cited 2022 6.8]. Available from: https://engauge-digitizer.updatestar.com/.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

Article  PubMed  PubMed Central  Google Scholar 

Sepesi B, Zhou N, William WN Jr, Lin HY, Leung CH, Weissferdt A, et al. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;164(5):1327–37.

Article  PubMed  PubMed Central  Google Scholar 

Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, et al. Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity www.clinicaltrials.gov: www.clinicaltrials.gov; 2022 [Available from: https://www.clinicaltrials.gov/ct2/show/NCT02919683?term=NCT02919683&draw=2&rank=1.

Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, et al. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8(+) Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res. 2020;26(13):3211–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leary A, Rouge TDLM, Lortholary A, Asselain B, Alexandre J, Floquet A, et al. Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study. Ann Oncol. 2021;32(suppl_5):S725–72.

Google Scholar 

Hong MH, Kim CG, Kim DH, Lim SM, Ahn BC, Kim SH, et al. 860MO Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2021;32:S787.

Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, et al. A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma. Clin Cancer Res. 2023;29(3):548–59.

Article  CAS  PubMed  Google Scholar 

Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56.

Article  CAS  PubMed  Google Scholar 

Kelliher MA, Roderick JE. NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies. Front Immunol. 2018;9:1718.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111.

Article  PubMed  PubMed Central  Google Scholar 

Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol. 2022;86(Pt 3):137–50.

Article  CAS  PubMed  Google Scholar 

Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40(1):184.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells. Cancer Discov. 2021;11(5):1100–17.

Article  CAS  PubMed  Google Scholar 

Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Stanisavljevic D, et al. Programm